WallStSmart

Abbott Laboratories (ABT)vsConocoPhillips (COP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ConocoPhillips generates 32% more annual revenue ($59.38B vs $45.13B). ABT leads profitability with a 13.9% profit margin vs 12.3%. COP appears more attractively valued with a PEG of 1.14. COP earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

COP

Buy

56

out of 100

Grade: C

Growth: 2.0Profit: 6.5Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued
COPSignificantly Overvalued (-50.4%)

Margin of Safety

-50.4%

Fair Value

$73.94

Current Price

$113.87

$39.93 premium

UndervaluedFair: $73.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

COP4 strengths · Avg: 8.3/10
Market CapQuality
$139.96B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$1.35B8/10

Generating 1.3B in free cash flow

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

COP2 concerns · Avg: 2.0/10
Revenue GrowthGrowth
-5.3%2/10

Revenue declined 5.3%

EPS GrowthGrowth
-20.2%2/10

Earnings declined 20.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : COP

The strongest argument for COP centers on Market Cap, Price/Book, Operating Margin. PEG of 1.14 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : COP

The primary concerns for COP are Revenue Growth, EPS Growth.

Key Dynamics to Monitor

ABT profiles as a value stock while COP is a declining play — different risk/reward profiles.

ABT carries more volatility with a beta of 0.65 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

COP generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

ConocoPhillips

ENERGY · OIL & GAS E&P · USA

ConocoPhillips is an American multinational corporation engaged in hydrocarbon exploration. It is based in the Energy Corridor district of Houston, Texas.

Want to dig deeper into these stocks?